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2012.06.0Abstract The primary cellular mechanism responsible for osteolytic bone metastases is osteoclastic
activation. Preclinical models have shown that breast cancer cells can produce parathyroid hor-
mone-related protein (PTHrP), and other osteolytic molecules, which stimulate excessive osteoclas-
tic bone resorption and establishment of osteolytic lesions. It has been shown that PTHrP by itself
cannot directly induce osteoclastic activation, but it mediates its effect through the transactivation
of RANK-ligand (RANKL) gene on stromal and osteoblastic cells. Accordingly RANKL up-reg-
ulation has been considered as a prerequisite in virtually all conditions of cancer induced bone
destruction. Hence, therapeutic targeting of RANKL seems to be a rational approach to treat or
even to prevent the process of bone metastases.
In this review, we will focus on the unique patho-physiological aspects related to the evolution of
bone metastases in breast cancer, emphasizing the pivotal role of RANKL and some other key mol-
ecules in osteoclastic bone resorption. We will discuss the therapeutic interventions using bisphos-
phonates and RANKL inhibitors in patients with bone metastases and the outcome of this novel
approach.
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Approximately 65–75%of patients with advanced breast cancer
will develop bone metastases, which result in bone destruction
and skeletal-related events (SRE) [1]. During the last two dec-
ades, it has been shown that the process of osteolytic metastases
depends essentially on osteoclast-mediated bone resorption
rather than a direct destructive effect by the cancer cells [2]. This
has promoted the use of bisphosphonates, which are potent
inhibitors of osteoclastic bone resorption, in the treatment of al-
most all types of bone metastases [3,4]. Treatment with bisphos-
phonates (especially zoledronic acid) resulted in a signiﬁcant
decrease in the morbidity associated with bone metastases [5–
7]. However, many patients will continue to develop SREs, call-
ing for adopting novel strategies to manage these patients.
Perhaps, among the most important discoveries in the ﬁeld
of bone biology were those related to the role of the RANK-
ligand/RANK/Osteoprotegerin (OPG) system in the regula-
tion of osteoclastic function and bone remodeling [8,9]. This
has led to a better understanding of the process of bone resorp-
tion, which is considered a primary step in the evolution, and
progression of bone metastases.
Physiological bone remodeling
The adult skeleton is in a dynamic state of continuous coordi-
nated cycles of bone resorption and bone formation, a process
known as bone remodeling. In physiological bone remodeling,
there is a well-balanced interplay between osteoclasts – dissolv-
ing old bones – and osteoblasts – laying down new bones – in
order to maintain the structural bone integrity. Accordingly,
the amount and contour of new bone deposition by osteoblasts
are always equivalent to what has been resorbed by osteoclasts
(balanced & coupled remodeling) [10].
Bone resorption by osteoclasts disintegrates collagen (which
is the major organic component of osseous tissue), and releases
calcium and growth factors from the bone matrix. Ninety per-
cent of the proteins released consists of collagen degradation
products; while the remaining 10% consists of the matrix cyto-
kines and growth factors [11]. Importantly, bone matrix is con-
sidered as a storehouse for growth factors and cytokines. Large
amount of transforming growth factor-b (TGF-b) and insulin
growth factor (IGF) II along with ﬁbroblast growth factor,platelet-derived growth factor, and other cytokines are pro-
duced by the stromal and immune cells and are stored within
the mineralized bone matrix [10,11]. These factors can mediate
cellular interaction – in a paracrine fashion – with cancer cells,
which is a critical step in the development and progression of
bone metastases. Although termed ‘‘growth factors’’, they do
not necessarily induce a direct stimulation of cancer cell prolif-
eration, as they can also indirectly promote angiogenesis and
osteoclastogenesis, which in turn would remodel the skeleton
to accommodate tumor growth [12,13].Osteoclastogenesis
Osteoclastogenesis is an extremely complex process, which is
predominately controlled by three members of the tumor
necrosis factor (TNF) family of receptors and ligands known
as RANK, RANKL and OPG [8,9,14].
RANK (Receptor Activator of Nuclear Factor-kappa B) is
a surface receptor mainly expressed on mature osteoclasts and
their progenitors [14,15]. Its primary function is to induce
osteoclastogenesis and control calcium metabolism [16]. While
RANK expression has been primarily observed on osteoclasts,
recent studies have demonstrated RANK expression on tumor
cells, including breast cancer cell lines and tissue specimens of
breast cancer patients which may suggest a role of this receptor
in the migration and metastatic behavior of such cancer cells
[17,18] as will be discussed later.
RANKL is a polypeptide that belongs to type II transmem-
brane proteins [9,14]. RANKL is found on the surface of oste-
oblasts and bone stomal cells but may be also found in a
soluble form within the bone microenvironment. In the pres-
ence of low levels of macrophage colony-stimulating factor
(M-CSF), RANKL can generate osteoclasts from hematopoi-
etic cells [12,14]. It binds to its receptor RANK on preosteo-
clasts and mature osteoclasts. Signaling through RANK
would then activate transcription factors such as nuclear factor
kappa beta, which leads to the differentiation of osteoclast
progenitors and limits apoptosis of mature osteoclasts
[15,19,20]. Many other molecules like parathormone (PTH),
parathyroid hormone related protein (PTHrP) 1, 25-
dihydroxyvitamin D, TNF, interleukin (IL)-1 and IL-11 can
also induce osteoclastogenesis [12]. A curious observation
many years ago was the ﬁnding that osteoclasts do not express
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have shown that these bone resorbing agents are able to induce
osteoclastic activation via the up-regulation of RANKL
expression by osteoblasts, stromal cells and other immune cells
(e.g. pre-B lymphocytes and activated T-cells) [20,21].
Osteoclastic suppression
Importantly, under physiological conditions, the stimulatory
effects of RANKL on osteoclasts are opposed by another mol-
ecule known as OPG, which is also secreted by the osteoblasts
and stromal cells [9,14,22]. In contrast to all other TNF recep-
tor family members, OPG lacks the transmembrane and cyto-
plasmic domains and acts as a soluble decoy receptor speciﬁc
for RANKL [22]. OPG competes with RANK for RANKL,
thus it prevents the RANKL–RANK interaction on the osteo-
clast cell membrane. When RANKL binds to OPG, osteo-
clastogenesis is markedly inhibited leading to cessation of
bone resorption [20,22].
Conceptually, the level of osteoclastogenesis and bone
remodeling is primarily regulated by a very delicate balance
in the RANKL/OPG ratio, such that a relative decrease in
OPG results in excessive bone resorption whereas a relative in-
crease in OPG inhibits resorption [14,15,23].
Breast cancer bone metastases
Breast cancer is a frank example of neoplasms that display an
extraordinary afﬁnity to grow in bone. The mechanisms under-
lying this osteotropism are complex and involve some peculiar
characteristics of both the breast cancer cells and the bone ma-
trix to which these tumors metastasize (soil and seed concept)
[13]. Accordingly, breast cancer cells should possess certain
properties that enable them to grow in bone, while the bone
matrix provides the suitable microenvironment, which facili-
tates growth of these cells.
The bone matrix is considered unique among target tissues
affected by cancer, as it is continuously enriched by bone-de-
rived growth factors and cytokines attributed to osteoclastic
activity during the physiological process of bone remodeling
as discussed earlier. This would render the bone microenviron-
ment as an appropriate fertile soil, which can attract and sup-
port the growth of circulating tumor cells, thus contributing to
the pathogenesis of bone metastases [13,24].
Chemotaxis
Chemotaxis of circulating tumor cells and the stromal cells
within the bone microenvironment is an essential component
of bone metastasis. Bone resorption products such as type I
collagen fragments, TGFb, and IGFs have been shown to
stimulate chemotaxis of breast cancer cells [13,24,25,26].
More recently, the role of chemokine receptors in chemo-
taxis of breast cancer cells to the bone microenvironment has
been described. It is well known that the circulating leukocytes
and stem cells use chemokine receptors (CXCR4) for homing
to the bone marrow, where an excessive amount of their corre-
sponding chemokine; SDF-1 is present [27]. Importantly, the
overexpression of CXCR-4 has been reported in around 30%
of primary breast cancer cells, and it has been also shown to
mediate the movement of malignant cancer cells to speciﬁcorgans especially bone where SDF-1a is abundant [28,29]. In
a more recently published trial CXCR4 expression in primary
breast cancer was signiﬁcantly associated with subsequent
development of bone metastases in these patients [30].
Several studies have also implicated RANKL in the process
of chemotaxis. As mentioned earlier, human breast cancer cell
lines and tissue specimens are reported to express RANK pro-
tein on their surface and it has been suggested that RANKL
may act as a chemotactic factor for these cancer cells [18].
The rich source of RANKL within the bone microenvironment
would attract RANK expressing tumor cells to migrate to the
bone. The correlation of high RANK expression with osteot-
ropism in murine models was demonstrated across many tu-
mor cell types, including breast cancer [18]. Santini et al. has
recently provided the ﬁrst clinical evidence of the role of
RANK expression in primary tumors as a predictive marker
of bone metastasis. In their study which included 93 patients
with early breast cancer, those with ‘‘RANK-positive’’ tumors
had a signiﬁcantly higher rate of bone metastasis compared to
patients with tumors, which had low or negative RANK
expression [17]. These data suggest that investigating the
RANK/RANKL pathway might open new venues in predict-
ing bone recurrence and may also identify a subgroup of pa-
tients, which are at a higher risk of developing skeletal
metastasis [31].Growth of bone metastasis
It should be noted that unlike other tissues, bone is mainly
composed of hard-mineralized tissue; hence it is more resistant
to invasion and destruction by cancer cells compared to other
metastatic sites [32]. Osteoclasts have been described as the
most efﬁcient cells to induce bone resorption ‘‘bone-resorbing
machines’’ [12]. Therefore, in order to grow within the bone
matrix, the cancer cells must possess the capacity to induce
osteoclastic activation, which is the main cellular mechanism
for cancer induced bone destruction [20,29]. Increased osteo-
clastic bone resorption would then provide the space in which
cancer cells can grow and induce further molecular interac-
tions with the different cytokines within the bone
microenvironment.
Most evidence indicates that breast cancer cells can induce
osteoclastic activation through the release of soluble mediators
such as IL-1, IL-6, 1L-8, prostaglandin E2, TNF and most
importantly, PTHrP [2,32]. PTHrP, which is expressed in
around 50% of primary breast cancers [33,34] has been shown
to play a causal role in the pathogenesis of breast cancer–med-
iated osteolytic metastases [2,23,35]. In animal models, intra-
cardiac injection of breast cancer cell lines (MDA-MB-231)
engineered to overexpress PTHrP, resulted in a signiﬁcant in-
crease in the number of osteolytic metastases [35].
Several clinical studies have shown that metastatic breast
cancer cells in bone express PTHrP more frequently than in
other non-skeletal metastases or in the primary tumor
[33,34,36]. However, it is not very clear whether PTHrP expres-
sion would promote the development of bone metastases in
these patients, or that the bone matrix provides a favorable
microenvironment, which is conducive to PTHrP production
by breast cancer cells when these cells are already within bone
matrix [36]. It may seem true that the ability of breast cancer
cells to produce PTHrP in response to cross-talks within the
110 H.A. Azim et al.bone microenvironment is more important to the development
of skeletal metastases than the expression of PTHrP by the pri-
mary breast cancer cells.
More recently, it has been shown that PTHrP may have
roles in breast cancer bone metastasis independent of its roles
in enhancement of osteoclastic function. PTHrP plays an
important role in modulating the angiogenic and bone osteo-
lytic actions of VEGF [37]. Furthermore, PTHrP up-regulates
the expression of matrix metalloproteinase-13 in breast cancer
cells, that can degrade bone matrix thus adding further inva-
sive characters to the bone metastatic process [38]. These data
strongly suggest that PTHrP represents a rational target to ex-
plore for the treatment of bone metastases in breast cancer. In
a mouse model, neutralizing antibodies against PTHrP de-
creased both the size of osteolytic lesions and tumor area in
bone [35]. A humanized monoclonal antibody targeting
PTHrP, was under development in Japan but the research
has been suspended [39]. At the present time and to the best
of our knowledge no clinical study is under way.
Other factors like M-CSF, IL-11, VEGF contribute to oste-
olytic lesions via RANKL up-regulation by osteoblasts and
stromal cells [13]. A unique exception of osteolytic cytokines
expressed by breast cancer cells is IL-8, which seems to operate
as a RANKL dependent as well as RANKL independent fac-
tor that can directly stimulate osteoclastic bone resorption [40].
Therefore, it has been proposed that IL-8 might be involved in
the very early stage of osteoclastic bone resorption, which will
be followed by the dominant action of PTHrP at a later phase
of bone destruction [41].
The vicious cycle of bone destruction
The widely accepted soil and seed model of osteolytic bone
metastasis in breast cancer is based on the hypothesis that
the TGF-b (which is released from the bone matrix during
osteoclastic resorption) induces tumor cell production of oste-
olytic factors including PTHrP and IL-11.This causes stromal
cells to secrete RANKL, thus increasing osteoclast number
and function with subsequent osteolysis with more TGF-b
being released from bone [13,39].
TGF-b which is deposited in the bone matrix by osteoblasts
and released and activated during osteoclastic resorption is not
the most abundant growth factor in bone, but it plays the most
signiﬁcant role in the progression of osteolytic metastases [42].
In pre-clinical models, the role of bone-derived TGF-b to stim-
ulate PTHrP production by breast cancer cells and enhance
their growth in bone is well established [43,44]. TGF-b binds
to its surface heterodimeric receptor, and mediates its func-
tions through the intracellular mediators known as Smad pro-
tein family (cytoplasmic mediators of most TGF-b signals) and
the Mitogen-activated Protein Kinase (MAP Kinase), which
enhances PTHrP secretion by breast cancer cells [42,44]. In
preclinical models, TGF-b signaling blockade inhibits PTHrP
secretion by breast cancer cells and suppresses the develop-
ment of bone metastases [45,46]. TGF-b also promotes osteo-
lytic metastases by stimulating tumor expression of matrix
metalloproteinases enzymes and increasing angiogenesis [47].
The fact that TGF-b is abundant in bone and can enhance
PTHrP expression by cancer cells makes it an important target
for the treatment of breast cancer bone metastases. However,
although TGF-b acts as a tumor promoter in advanced cancer,it actually functions as a tumor suppressor in early phases of
cancer [48]. This dual role of TGF-b could pose a challenge
when targeting the TGF-b signaling for cancer treatment
[49]. Although TGF-b inhibitors have been investigated for
other types of cancers, however, to date, there have been no
clinical trials studying the effect of a TGF-b-related therapy
for breast cancer with bone metastases.
IGF is another important molecule, which is also released
during bone resorption and likely has signiﬁcant effects on tu-
mor cell growth [31]. Experimental evidence suggests that
IGFs promote breast cancer cell proliferation within the bone
matrix and neutralizing antibodies against IGF-I receptor
markedly impaired the growth-stimulating effects of osteolysis
on the tumor cells [2,13]. IGF inhibitors are in early phases of
clinical trials in many solid tumors, but not as yet in the setting
of bone metastases. Enhanced resorption of the mineralized
bone matrix is also associated with excessive elevation of extra-
cellular calcium. The levels of calcium in the vicinity of resorb-
ing osteoclasts are many folds higher than the level of systemic
calcium [50]. It has been shown that calcium-sensing receptors
(CaR) are expressed on normal mammary epithelium and
respond to low levels of ionized calcium by increasing the pro-
duction of PTHrP [51,52]. Following the classic negative feed-
back, PTHrP stimulates osteoclasts to resorb bone, releasing
calcium, and signaling back through the CaR to reduce PTHrP
production. However, transformation into a malignant pheno-
type may involve reversal of the normal negative feedback that
exists between CaR and PTHrP leading to stimulation rather
than inhibition of PTHrP when extracellular calcium is ele-
vated [53]. It has been shown that breast cancer cells express
the CaR, which would then participate in stimulating the
production of PTHrP by tumor cells within the bone matrix,
thus adding more to the process of osteoclastic activation
[53]. Interestingly, Mihai et al. have identiﬁed CaR predomi-
nantly expressed in patients who developed bone rather than
visceral metastases [54]. These data may suggest CaR expres-
sion as a potential new predictive biomarker for bone metasta-
ses in breast cancer patients. Whether patients with CaR-
positive tumors are more likely to develop bone metastases
and whether they could beneﬁt more from prophylactic
treatment with bisphosphonates or RANKL inhibitors, are
important questions that need to be addressed in prospective
trials.
It seems true that many products of osteolysis join the con-
cert to evoke further PTHrP release and worsening osteolysis
in addition to supporting the growth of breast cancer cells
within the bone [55,56]. This reciprocal feedback between tu-
mor cells and the bone microenvironment has been referred
to as the ‘‘vicious cycle’’ of bone destruction, in which osteo-
clast is the key cellular player, whereas PTHrP, RANKL and
TGFb are the main molecular co-players in a master scene
known as the ‘seed and soil’ hypothesis (Figure 1).
Treatment of bone metastases in breast cancer
Identifying the cellular and molecular components that pro-
mote the development of bone metastasis is an essential step
to provide a rational treatment for skeletal metastases. The
theme of therapy should be directed toward reduction of
osteoclast differentiation and activation (with subsequent
reduction in bone resorption and SRE.
PTHrP: parathyroid hormone related protein; TGFβ: transforming growth factor beta;  
Ca: calcium; IGF1: insulin growth factor 1; OPG: osteoprotegerin; RANKL: RANK ligand
Figure 1 Diagrammatic illustration of the interplay between breast cancer cells expressing PTHrP, osteoblasts, osteoclasts and bone
matrix. Breast cancer cells secrete PTHrP, which stimulate osteoblast production of RANKL while OPG levels are reduced leading to
enhanced osteoclastogenesis and increased bone resorption. Consequently the local milleau will be enriched by growth factors and other
products of osteolysis (extracellular Ca + 2 and collagen fragments) which will induce: 1-stimulation of PTH-rP secretion (via TGF,
Ca + 2), 2-stimulation of tumor growth (via TGF, IGF1) and 3-chemotaxis of circulating tumor cells to arrest in bone matrix (via IGF1,
collagen fragments). This evokes further PTHrP release with worsening osteolysis, in addition to supporting the growth of breast cancer
cells within the bone matrix. This reciprocal feedback between tumor cells and the bone microenvironment has been referred to as the
‘‘vicious cycle’’ of bone destruction.
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Bisphosphonates inhibit osteoclast formation and migration,
increase production of OPG by osteoblasts and promote osteo-
clast apoptosis, resulting in suppression of physiological and
pathological bone resorption [3,57]. They also reduce the re-
lease of bone-derived growth factors and cytokines associated
with osteoclastic bone resorption, which potentially enhances
tumor cell growth and proliferation in bone matrix [57,58].
Moreover, there are extensive data from preclinical studies,
that these agents can also exert direct antitumor effects via
inhibition of tumor cell adhesion, invasion, and proliferation,
in addition to induction of apoptosis [59]. Furthermore, the
Nitrogen containing bisphosphonates (e.g. zoledronic acid)
may also act indirectly on tumor cells through antiangiogenic
and immuno-modulatory mechanisms [59,60].
Zoledronic acid is known to be the most potent bisphosph-
onate to date [3,57]. Standard doses of zoledronic acid have
been consistently reported to induce selective stimulation of
cd T cells, which exert a beneﬁcial anti-tumor function
in vivo [60]. However, we would like to refer to the recent work
by Fournier et al. [58] suggesting that the main anti-tumor ef-
fect of clinically relevant doses of bisphosphonates on breast
cancer, is essentially mediated via the inhibition of osteo-
clast-mediated bone resorption rather than a direct cytotoxic
effect. This supports the argument that targeting the bone
microenvironment and not necessarily the primary tumor
may be the corner stone for the beneﬁcial anti-tumor effectsof bisphosphonates (if any) during the adjuvant phase of
breast cancer.
In clinical practice, four bisphosphonates (clodronate,
pamidronate, ibandronate, and zoledronic acid) have been
widely used to treat breast cancer patients with bone metasta-
ses. In placebo controlled studies, these agents resulted in a sig-
niﬁcant decrease in the morbidity associated with bone
metastases [4,5,7]. In a large double-blind phase 3 study com-
paring zoledronic acid with pamidronate, patients receiving
the former had a signiﬁcant 21% reduced risk of developing
a SRE [61]. Subsequent follow-up, zoledronic acid could fur-
ther reduce the risk of experiencing a second SRE by about
one third compared with pamidronate, denoting the impor-
tance of maintaining these patients on a potent anti-resorption
drug; even after the development of a SRE.
Targeting RANKL
As previously mentioned, RANKL is considered as the main
molecular prerequisite in bone destruction. Therefore, target-
ing RANKL seems to be a very rational approach to treat
bone metastases. Following the discovery of OPG, it was
thought that increasing OPG levels would be an effective
way to inhibit the bone resorbing effects of RANKL [62].
Administration of an Fc-OPG construct has shown promise
as a potential therapy in animal models of bone metastasis
[62,63]. Accordingly, a genetically engineered recombinant
OPG-Fc construct (AMGN-0007) was developed as a poten-
tial therapeutic agent for patients with bone metastases. In a
112 H.A. Azim et al.double-blind trial, AMGN-0007 was at least as effective as
pamidronate in reducing bone resorption marker levels in mul-
tiple myeloma and breast cancer patients [64]. However, there
were some concerns that prevented further development of this
drug in clinical trials. This agent had a short half-life, which
raised some concerns on dose scheduling for clinical use. Fur-
thermore, OPG is not speciﬁc to RANKL, as it can also block
TRAIL [TNF related apoptosis inducing ligand] which is an-
other ligand belonging to TNF family [65]. TRAIL is consid-
ered a very important component in natural immunity
against cancer and is the principal mediator of tumor cell
death induced by host immune cells [66]. Thus binding of phar-
macological doses of OPG to TRAIL may protect breast can-
cer cells from undergoing TRAIL-induced apoptosis [67]. This
may bear a potential risk of tumor growth with the long-term
use of this drug. Therefore and as an alternative approach, an
antibody speciﬁc to RANKL was developed which simulates
the beneﬁcial effects of OPG on bone health while avoiding
any potential reaction with TRAIL [68].
Denosumab is a fully human anti-RANKL monoclonal
antibody, but unlike OPG, it does not have any potential reac-
tion with TRAIL [68]. In a recent large double-blind, random-
ized phase III study involving 2049 women with metastatic
breast cancer, denosumab at a dose of 120 mg repeated every
4 weeks was compared to the standard 4-weekly zoledronic
acid [69]. Denosumab was shown to signiﬁcantly delay time
to ﬁrst SRE [HR: 0.82 (95% CI: 0.71–0.95; p= 0.01], time
to ﬁrst and subsequent SRE (p= 0.001) and malignant hypo-
calcaemia (p= 0.007).
The difference in efﬁcacy between denosumab and zoled-
ronic acid may be attributed to the difference in the mechanism
of action between RANKL inhibition and bisphosphonate.
Bisphosphonates act only when taken up by mature, actively
resorting osteoclasts, and thus residual osteoclasts can still
be observed in bisphosphonate-treated bones [62,63]. On the
other hand, RANKL inhibitors block the activation, survival,
and differentiation of osteoclasts from their precursors result-
ing in complete absence of osteoclasts in the treated bones [63].
Currently, several phase III studies are ongoing to deter-
mine whether denosumab can also prevent the development
of bone metastasis in the adjuvant phase of breast cancer.
RANKL beyond bone resorption
More interestingly, the RANK/RANKL pathway may also
have a potential importance in breast cancer tumorigenesis.
Two recent studies in animal models have demonstrated that
RANKL mediates progestin-induced mammary breast cancer.
In these studies, inhibition of RANKL function could result in
a markedly decreased incidence and delayed onset of proges-
tin-driven breast cancers. Blocking the RANKL not only re-
duced breast tumor formation but also decreased the spread
of the cancer cells to the lungs. These data suggest that deno-
sumab may be further considered as a novel approach to the
prevention and/or treatment of hormone receptor positive
breast cancer [70,71].
In summary, the development of established bone metasta-
ses involves complex, reciprocal interactions between cancer
cells and the bone microenvironment, with a resultant vicious
cycle of tumor cell growth and bone destruction. The afﬁnity
of breast cancer cells to bone is deﬁned not only by a hostingmicroenvironment favoring the survival of breast cancer cells,
but also by the capacity of speciﬁc breast cancer cells to collab-
orate with stromal/osteoblastic cells in recruiting osteoclasts
through the RANK/OPG/RANKL system. Interference with
the micro environmental support of cancer cells via bisphos-
phonates has shown to be a valid approach to treat bone
metastases. The introduction of denosumab will certainly pro-
vide an extra useful tool in the treatment and perhaps the pre-
vention; of such a catastrophic complication of cancer.
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